Jane Street
SPRO icon

Jane Street’s Spero Therapeutics SPRO Stock Holding History

Jane Street’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$90.1K Sell
38,500
-100
-0.3% -$237 ﹤0.01% 10698
2025
Q4 		$89.9K Buy
+38,600
New +$89.6K ﹤0.01% 10235

Other funds holding SPRO

GP
GSK plc London $599M AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street's SPRO Position: Q1 2026 in Review

Jane Street reduced its Spero Therapeutics (SPRO) stake by 33% in Q1 2026, selling an estimated $123K and leaving 106,345 shares worth $249K. The position accounts for ﹤0.01% of the portfolio, ranked #9639.

Jane Street first reported a position in SPRO in Q1 2021 and has held it in 7 quarters since. The position peaked at $369K in Q4 2025. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

  • Jane Street held 106,345 shares of Spero Therapeutics worth $249K as of Q1 2026.
  • Jane Street sold 51,999 Spero Therapeutics shares in Q1 2026, an estimated $123K.
  • Spero Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #9639 holding.
  • Jane Street first reported a position in Spero Therapeutics in Q1 2021 and has held it in 7 quarters since.
  • Jane Street's Spero Therapeutics position peaked at $369K in Q4 2025.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.